CatalYm
CatalYm is a Germany-based biotechnology company running 5 late-stage cancer trials of Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma.
Overview
CatalYm, based in Planegg-Martinsried, Germany, is a biotechnology company. A private, venture-backed cancer immunotherapy company developing antibodies that neutralise GDF-15, a mechanism cancers use to resist treatment, with its lead candidate visugromab. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma. The largest, NCT07112196 (Visugromab in Cachexia International Trial), plans to enrol 518 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAscentawits Pharmaceuticals
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.